Characteristics of the studies included for meta-analysis (
n = 12), such as study design and information concerning length of follow-up, setting, source of data, participants, interventions and description of the MDT, comparison, outcomes, and risk stratification are presented in Additional file
5. All 23 studies included in the systematic review were in English. We identified 6 studies from the United States [
40,
45,
47,
48,
54,
55], 2 from Canada [
44,
55] and 10 from Europe, of which 5 were from the United Kingdom [
41,
43,
50,
56,
57], 2 from Spain [
36,
38], 1 from Sweden [
51], 1 from the Netherlands [
58] and 1 from Italy [
49]. There were also 3 articles from Asia, of which 2 were from China [
42,
59] and 1 from Singapore [
60]. One publication was respectively from Australia [
61] and another from New Zealand [
46]. Publication years were from 1990 to 2019. Four articles were published before 2000 [
50‐
52,
57], and 3 articles were from 2000 to 2009 [
38,
43,
49], while the majority (16 articles) was published between 2010 and 2019 [
36,
40‐
42,
45‐
47,
54‐
56,
58,
60‐
63]. Lengths of follow-ups were between 1 and 14 years, with a median of 3.8 years and a mean of 3.6 years. Study settings were mostly in tertiary care [
36,
38,
40,
43‐
47,
50,
54,
55,
57‐
59,
61]. There were 4 studies based in primary care [
42,
48,
49,
63], 3 in secondary care settings [
51,
56,
60] and 1 unknown [
41]. Three articles collected prospective data [
38,
50,
57]; all other analyses were carried out using retrospective data (electronic medical records, medical charts, databases with coding). The 12 articles which were combined for meta-analysis accounted for 545,829 patients. The participants’ characteristics at baseline were heterogeneous. According to our stratification system of choice for the population (SIGN) [
30], 21 studies had a population stratification categorised as high risk. This is explained by the fact that the population included in the studies could either have a DFU or a history of DFU [
45,
47,
50,
55,
57,
58,
60,
61], an amputation or a history of amputation [
36,
40,
43‐
45,
48,
51,
61], peripheral vascular disease (PVD) [
45,
56], or diabetic foot infection [
52,
61,
62]. Stratification of the population with PVD, neuropathy, cellulitis, osteomyelitis or Charcot foot is also categorized as a moderate to high-risk population [
41]. Four articles included both categories (high and low risk) [
38,
42,
49,
54] and 4 articles had a system of classification of their population or DFUs: surgery classification [
47], LEAs risk with King’s classification [
60], Wagner’s classification for ulcers [
59], and Texas University classification for DFUs [
54].
The specific podiatric interventions were all poorly described (without information concerning nature, intensity, duration, frequency) and very heterogeneous. In the 12 included studies, podiatric interventions are stated as contact with podiatry [
36,
40‐
42,
45,
49,
51,
55,
58,
59,
61,
63]. Thus, we classified the podiatric interventions as educational strategies [
38,
43,
50,
54,
57,
60], foot care strategies [
38,
43,
46,
50,
54,
56,
57,
60], offloading strategies [
43,
46,
48,
55‐
57], wound care and infection control strategies [
44,
48,
54], surgical strategies [
44,
47,
54], and stratification [
38,
42,
49]. Only a few studies had defined exposure to the interventions as a weekly exposure to podiatry [
56,
60], a regular follow-up in podiatry or monthly appointments [
38,
43,
50] or at least every 3 months [
57]. Concerning the role of the podiatrist, we decided a posteriori to distinguish their role according to their implication in the MDT. With this in mind, the podiatrist intervenes in a primary role in 8 articles (leading role or core of the team) [
36,
43,
44,
47,
48,
54,
55,
59]. Specifically, in these articles, the podiatrist formed the core of the team with endocrinologists [
36,
59], nurses [
43,
55], and vascular surgeons [
44,
47,
54]. Podiatrists are sole leaders in one article [
48]. In 8 articles, they had a secondary role (support to the MDT but without a leading role) [
45,
46,
49,
51,
56,
58,
60,
61] and in 2 articles, they had a tertiary role (external consultation when needed) [
38,
42]. Podiatrists’ role was similar to other team members in two articles [
50,
57] . Finally, in 3 articles, it was impossible to determine the level of the podiatrist’s implication in the MDT because no description of the team was provided. In one article [
52], it was a podiatry-established critical pathway and in the two others, it was with other lower-extremity specialists [
40,
41]. The MDTs composition was also variable; some MDTs showed care management in 2 levels of team members’ implication [
36,
42,
47,
49]. Finally, funding and conflict of interest in the included articles were clearly mentioned in the full text of 14 out of 23 articles [
36,
41‐
44,
47,
48,
51,
54,
55,
57,
60‐
62].